The expanding vaccine development pipeline, 1995-2008. (Q37637226)

21 August 2017

1 reference

title

The expanding vaccine development pipeline, 1995-2008. (English)

1 reference

21 August 2017

Matthew M Davis

1

1 reference

21 August 2017

Amy T Butchart

2

1 reference

21 August 2017

Margaret S Coleman

3

1 reference

21 August 2017

Dianne C Singer

4

1 reference

21 August 2017

John R C Wheeler

5

1 reference

21 August 2017

Angela Pok

6

1 reference

21 August 2017

Gary L Freed

7

1 reference

21 August 2017

language of work or name

English

0 references

publication date

21 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

28

1 reference

21 August 2017

5

1 reference

21 August 2017

1353-1356

1 reference

Decline in mortality due to varicella after implementation of varicella vaccination in the United States

21 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Impact of varicella vaccination on health care utilization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Economic Evaluation of the 7-Vaccine Routine Childhood Immunization Schedule in the United States, 2001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Childhood vaccine purchase costs in the public sector: past trends, future expectations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Why are pharmaceutical companies gradually abandoning vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Factors affecting U.S. manufacturers' decisions to produce vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Why certain vaccines have been delayed or not developed at all

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Estimating the cost of new drug development: is it really 802 million dollars?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

The price of innovation: new estimates of drug development costs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.11.007

10.1016/J.VACCINE.2009.11.007

7 January 2021

Identifiers

DOI

1 reference

21 August 2017

1 reference